Stock Research for AMGN

AMGN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AMGN Stock Chart & Research Data

The AMGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AMGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AMGN Due diligence Resources & Stock Charts

The AMGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AMGN Detailed Price Forecast - CNN Money CNN View AMGN Detailed Summary - Google Finance
Yahoo View AMGN Detailed Summary - Yahoo! Finance Zacks View AMGN Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View AMGN Trends & Analysis - Trade-Ideas Barrons View AMGN Major Holders - Barrons
NASDAQ View AMGN Call Transcripts - NASDAQ Seeking View AMGN Breaking News & Analysis - Seeking Alpha
Spotlight View AMGN Annual Report - CompanySpotlight.com OTC Report View AMGN OTC Short Report - OTCShortReport.com
TradeKing View AMGN Fundamentals - TradeKing Charts View AMGN SEC Filings - Bar Chart
WSJ View Historical Prices for AMGN - The WSJ Morningstar View Performance/Total Return for AMGN - Morningstar
MarketWatch View the Analyst Estimates for AMGN - MarketWatch CNBC View the Earnings History for AMGN - CNBC
StockMarketWatch View the AMGN Earnings - StockMarketWatch MacroAxis View AMGN Buy or Sell Recommendations - MacroAxis
Bullish View the AMGN Bullish Patterns - American Bulls Short Pains View AMGN Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View AMGN Stock Mentions - StockTwits PennyStocks View AMGN Stock Mentions - PennyStockTweets
Twitter View AMGN Stock Mentions - Twitter Invest Hub View AMGN Investment Forum News - Investor Hub
Yahoo View AMGN Stock Mentions - Yahoo! Message Board Seeking Alpha View AMGN Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for AMGN - SECform4.com Insider Cow View Insider Transactions for AMGN - Insider Cow
CNBC View AMGN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AMGN - OTC Markets
Yahoo View Insider Transactions for AMGN - Yahoo! Finance NASDAQ View Institutional Holdings for AMGN - NASDAQ


Stock Charts

FinViz View AMGN Stock Insight & Charts - FinViz.com StockCharts View AMGN Investment Charts - StockCharts.com
BarChart View AMGN Stock Overview & Charts - BarChart Trading View View AMGN User Generated Charts - Trading View




Latest Financial News for AMGN


Amgen's postmenopausal osteoporosis drug wins FDA panel backing
Posted on Wednesday January 16, 2019

An advisory panel to the U.S. Food and Drug Administration said on Wednesday that benefits of Amgen Inc's osteoporosis treatment for postmenopausal women at high risk for fracture outweighed its risks and overwhelmingly voted for the drug's approval. The panel voted 16-1 in favor of the monthly injection developed jointly with Belgium-based UCB SA. The drug, Evenity, helps reduce the risk of fracture by increasing bone formation and inhibiting break down of bone minerals. The panel, however, raised concerns of cardiovascular safety risks linked to the drug, which FDA staff reviewers on Monday had cited as the main reason for convening the panel meeting.


Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab)
Posted on Wednesday January 16, 2019

THOUSAND OAKS, Calif. and BRUSSELS, Jan. 16, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture after reviewing safety and efficacy data from the pivotal Phase 3 studies. "We are pleased with the Committee's recommendation to approve EVENITY for the treatment of postmenopausal women with osteoporosis at high risk for fracture," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.


6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019
Posted on Wednesday January 16, 2019

Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.


The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen
Posted on Wednesday January 16, 2019

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs Jan. 15) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Avenue Therapeutics ...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.